| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.HYP.0000154082.72286.2A |
| P698 | PubMed publication ID | 15655123 |
| P50 | author | Ulf de Faire | Q29840595 |
| Suzanne Oparil | Q30029225 | ||
| Sverre E. Kjeldsen | Q45903512 | ||
| Björn Dahlöf | Q47156424 | ||
| Ole Lederballe-Pedersen | Q47156427 | ||
| Richard B Devereux | Q87223976 | ||
| P2093 | author name string | Hans Ibsen | |
| Markku S Nieminen | |||
| Ying Wan | |||
| Knut Borch-Johnsen | |||
| Kristian Wachtell | |||
| Lars H Lindholm | |||
| Frej Fyhrquist | |||
| Carl Erik Mogensen | |||
| Per Omvik | |||
| Stevo Julius | |||
| Michael H Olsen | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| losartan | Q410074 | ||
| hypertension | Q95566669 | ||
| P304 | page(s) | 198-202 | |
| P577 | publication date | 2005-01-17 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study | |
| P478 | volume | 45 |
| Q57642479 | Q57642479 |
| Q36351684 | 'Hypertension' and 'microalbuminuria': the bell tolls for thee |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q56970511 | 2013 ESH/ESC Guidelines for the management of arterial hypertension |
| Q34455476 | A maladaptive role for EP4 receptors in podocytes |
| Q57724014 | A novel role for calpain in the endothelial dysfunction induced by activation of angiotensin II type 1 receptor signaling |
| Q57947799 | Age-related change in endothelial and microvessel function and therapeutic consequences |
| Q47098883 | Albuminuria and kidney function as prognostic marker of left ventricular mass among South Asians with hypertension |
| Q37297655 | Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes |
| Q36285590 | Albuminuria-reducing effect of angiotensin II receptor blocker plus hydrochlorothiazide combination therapy in renal transplant recipients |
| Q46866935 | Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy |
| Q37369097 | Angiotensin blockade to reduce microvascular damage in diabetes mellitus |
| Q39988729 | Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients: the lower, the better? |
| Q37019596 | Arterial aging: pathophysiological principles |
| Q38148620 | Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand? |
| Q81518507 | Assessment of urinary albumin excretion might improve cardiovascular outcome in patients with hypertension |
| Q33852790 | Association between coronary artery calcification progression and microalbuminuria: the MESA study |
| Q36268154 | Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study |
| Q45772264 | Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment |
| Q34994258 | Association of renal biomarkers with 3-month and 1-year outcomes among critically ill acute stroke patients |
| Q39294049 | Associations of proteinuria and the estimated glomerular filtration rate with incident hypertension in young to middle-aged Japanese males |
| Q47255994 | Bariatric Surgery can Reduce Albuminuria in Patients with Severe Obesity and Normal Kidney Function by Reducing Systemic Inflammation |
| Q37042326 | Being overweight modifies the association between cardiovascular risk factors and microalbuminuria in adolescents |
| Q59489249 | Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy |
| Q51306844 | Benefits of a 12-week lifestyle modification program including diet and combined aerobic and resistance exercise on albuminuria in diabetic and non-diabetic Japanese populations. |
| Q90668349 | Bidirectional and Temporal Association Between Hypertension and Microalbuminuria: A Longitudinal Study in Chinese Adults |
| Q38429854 | Blood pressure control versus atrial fibrillation management in stroke prevention |
| Q38210401 | Blood pressure, albuminuria and renal dysfunction: the 'chicken or egg' dilemma |
| Q37151932 | Cardiac and vascular protection: the potential of ONTARGET. |
| Q37950891 | Cardiorenal connection in chronic kidney disease. |
| Q94536669 | Cardiovascular Literature—Beyond Nephrology |
| Q49912898 | Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial. |
| Q37097700 | Cardiovascular disease in transplant recipients: current and future treatment strategies |
| Q37251892 | Cardiovascular protection for all individuals at high risk: evidence-based best practice |
| Q35108899 | Changes in albuminuria predict mortality and morbidity in patients with vascular disease |
| Q89545116 | Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? |
| Q89037266 | Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice |
| Q36672186 | Clinical commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria |
| Q33727755 | Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat |
| Q36446320 | Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials |
| Q41893294 | Comparison between immunoturbidimetry, size-exclusion chromatography, and LC-MS to quantify urinary albumin |
| Q37367740 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria |
| Q38879739 | Cumulative Exposure to Systolic Blood Pressure During Young Adulthood Through Midlife and the Urine Albumin-to-Creatinine Ratio at Midlife |
| Q97420327 | Danhong Injection for the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis |
| Q39724413 | Determination of Urine Albumin by New Simple High-Performance Liquid Chromatography Method. |
| Q86179502 | Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study |
| Q41585268 | Differing Effects of Aliskiren/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection |
| Q44943187 | Dihydropiridinic Calcium-Channel Antagonists in the 2007 ESH/ESC Hypertension Guidelines |
| Q37417576 | Direct renin inhibitors: ONTARGET for success? |
| Q37932631 | Dissociation of blood pressure and resistance artery structure: potential clinical implications |
| Q48093775 | Does CPAP therapy alter urinary albumin level in adult patients with moderate to severe obstructive sleep apnea syndrome? |
| Q49667745 | Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. |
| Q79796272 | Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension |
| Q83632726 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria |
| Q43492164 | Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial |
| Q44224759 | Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART. |
| Q47994395 | Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes |
| Q38373937 | Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
| Q34444944 | End organ damage in hypertension |
| Q37888664 | End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function |
| Q26767156 | Endothelin |
| Q35182125 | Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner |
| Q36619734 | Endothelin-1 and the kidney--beyond BP. |
| Q36384453 | Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q51352466 | Evolution of target organ damage by different values of self-blood pressure measurement in untreated hypertensive patients. |
| Q38881453 | Exercise-induced albuminuria is related to metabolic syndrome. |
| Q36842388 | Extended prognostic value of urinary albumin excretion for cardiovascular events |
| Q82535423 | Factors associated with brachial-ankle pulse wave velocity in the general population |
| Q57023942 | Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure |
| Q90068994 | Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria |
| Q37100961 | Global cardiovascular risk assessment in the management of primary hypertension: the role of the kidney |
| Q30426632 | Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus |
| Q37776401 | Have we fallen off target with concerns surrounding dual RAAS blockade? |
| Q36276031 | Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships |
| Q33571796 | Heritability of urinary traits that contribute to nephrolithiasis |
| Q35058809 | High-normal albuminuria and risk of heart failure in the community |
| Q37624284 | Hypertension and Diabetes: what are the pros to treating early surrogates? |
| Q34131899 | Hypertensive nephropathy: prevention and treatment recommendations |
| Q49719259 | Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure |
| Q57816063 | Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial) |
| Q37531889 | Integrating albuminuria and GFR in the assessment of diabetic nephropathy |
| Q34878952 | Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. |
| Q91860329 | Interrelations Between Arterial Stiffness, Target Organ Damage, and Cardiovascular Disease Outcomes |
| Q83810771 | Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment? |
| Q82286617 | Is it time to change the definition of normal urinary albumin excretion? |
| Q84896853 | Left ventricular mass index as a predictor of new-onset microalbuminuria in hypertensive subjects: a prospective study |
| Q59489229 | Long-term prevention of diabetic nephropathy: an audit |
| Q36799139 | Low-grade albuminuria and cardiovascular risk : what is the evidence? |
| Q38714429 | Management of resistant hypertension: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology |
| Q84946019 | Methodological evaluation and comparison of five urinary albumin measurements |
| Q37134407 | Microalbuminuria and C-reactive protein as a predictor of coronary artery disease in patients of acute chest pain |
| Q36255435 | Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risk? |
| Q43014156 | Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease |
| Q38008566 | Microalbuminuria as surrogate endpoint in therapeutic trials |
| Q38897199 | Microalbuminuria in primary hypertension: a guide to optimal patient management? |
| Q61866080 | Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension |
| Q33888381 | Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC study |
| Q46375259 | New risk markers may change the HeartScore risk classification significantly in one-fifth of the population |
| Q37219032 | Novel therapeutic approaches to chronic kidney disease |
| Q33975753 | Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival |
| Q34995916 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study |
| Q53207877 | Overview of the i-SEARCH Global Study : Cardiovascular Risk Factors and Microalbuminuria in Hypertensive Individuals. |
| Q37219039 | Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease |
| Q44720727 | Percutaneous transluminal angioplasty for peripheral artery disease confers cardiorenal protection |
| Q34013444 | Physical activity is inversely associated with microalbuminuria in hypertensive patients at high cardiovascular risk: data from I-SEARCH. |
| Q36892439 | Potential benefits of renal diets on cardiovascular risk factors in chronic kidney disease patients |
| Q37095324 | Preclinical cardiorenal interrelationships in essential hypertension |
| Q28196527 | Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective |
| Q37231756 | Prevalence of microalbuminuria and associated electrocardiographic abnormalities in an Indo-Asian population |
| Q37041653 | Prevalence of microalbuminuria in hypertensive patients and its associated cardiovascular risk in clinical cardiology: Moroccan results of the global i-SEARCH survey - a sub-analysis of a survey with 21,050 patients in 26 countries worldwide. |
| Q38034807 | Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. |
| Q46969529 | Proteinuria and renal disease: prognostic value of urine dipstick testing for leukocytes |
| Q92625964 | Proteinuria as an independent predictor of stroke: Systematic review and meta-analysis |
| Q37964266 | Proteinuria: detection and role in native renal disease progression |
| Q36392674 | Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. |
| Q61455868 | Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial |
| Q56970710 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document |
| Q36330445 | Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine |
| Q37200557 | Reduction of proteinuria with angiotensin receptor blockers |
| Q50104171 | Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study |
| Q37200548 | Renal disease: a common and a silent killer |
| Q34877735 | Renal function in diabetic nephropathy |
| Q37201509 | Renal senescence in 2008: progress and challenges |
| Q36784673 | Renin-angiotensin system and cardiovascular risk |
| Q37838428 | Reno-cerebrovascular disease: linking the nephron and neuron |
| Q57312413 | Réduire l’albuminurie : est-ce un facteur indépendant de diminution du risque cardiovasculaire ? |
| Q61797815 | SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice |
| Q37727775 | Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events |
| Q33827573 | Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings. |
| Q37593682 | Should albuminuria be a focus of antihypertensive therapy goals? |
| Q37701187 | Study the association of chronic obstructive pulmonary disease with early endothelial dysfunction and its impact on cardiovascular system by estimating urinary albumin creatinine ratio |
| Q39165618 | Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. |
| Q37739439 | Subclinical organ damage and cardiovascular risk prediction |
| Q38786854 | Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression |
| Q36302833 | Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers |
| Q42674666 | The Bedtime Administration Ameliorates Blood Pressure Variability and Reduces Urinary Albumin Excretion in Amlodipine-Olmesartan Combination Therapy |
| Q37807824 | The Cardiovascular Continuum extended: Aging effects on the aorta and microvasculature |
| Q35914820 | The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease |
| Q43048709 | The L/N-type calcium channel blocker, Cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes |
| Q43650485 | The accuracy of predicting cardiovascular death based on one compared to several albuminuria values |
| Q81612481 | The aging kidney |
| Q37743531 | The cardiovascular continuum refined: A hypothesis |
| Q38656052 | The population-based prevalence of albuminuria in children. |
| Q34800794 | The prevalence and characteristics of microalbuminuria in the general population: a cross-sectional study |
| Q37511594 | The prevalence, characteristics, and clinical significance of abnormal albuminuria in patients with hypertension |
| Q37788947 | The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor |
| Q33378672 | The relationship between proteinuria and coronary risk: a systematic review and meta-analysis |
| Q37874892 | The role of angiotensin receptor blockers in diabetic nephropathy |
| Q47346059 | Under-treatment of hypertension and hypercholesterolemia in children and adolescents with type 1 diabetes- Long term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use. |
| Q36675396 | Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management |
| Q42683387 | Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker |
| Q79579890 | Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults |
| Q35753558 | Urine Albumin Excretion Is Associated with Cardiac Troponin T Detected with a Highly Sensitive Assay in a Community-Based Population |
| Q43214286 | Usefulness of RAS inhibition depends on baseline albuminuria. |
| Q83200607 | [Albuminuria : prognostic marker or therapeutic goal?] |
| Q80795333 | [Chronic kidney disease and the cardiovascular system] |
| Q83907685 | [Diabetic nephropathy] |
| Q46001968 | [How to carry out the search of kidney disease in patients with cardiovascular disease?]. |
Search more.